Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | TNKS | O95271 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314822 | 0.69 | DAO (0.48) | KDM4EALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL15821689 | 0.65 | KDM4E (0.50) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL24840442 | 0.64 | ALOX5 (0.40) | KDM4EALDH1A1GSK3BPARP15HSD17B10 | |
| SCHEMBL6111813 | 0.64 | KDM4E (0.48) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL4950563 | 0.64 | PARP1 (0.48) | KDM4EPARP1CA12CA9ALDH1A1 | |
| Benzoylenurea SCHEMBL5072763 | 0.64 | KDM4E (0.95) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL12506530 | 0.63 | ADORA2B (0.55) | KDM4EALDH1A1PDE3BPDE3AMEN1 | |
| Benzoylenurea SCHEMBL10765540 | 0.62 | KDM4E (0.91) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL3426314 | 0.62 | KDM4E (0.53) | KDM4EPARP1CA12CA9ALDH1A1 | |
| SCHEMBL7034913 | 0.62 | KDM4E (0.53) | KDM4EPARP1CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2015047058-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 주식회사 두산 | 2015-04-02 | — | — | WO | disclosed |
| EP-2222660-B1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20110165118-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1686999-B1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008031888-A2 | CONDENSED PYRIMIDINONES ACTIVE ON GLUTAMATERGIC RECEPTORS | CAMPIANI GIUSEPPE (IT) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007117995-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247554-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | KDM4E 1140/4885PARP1 618/4885CA12 4637/4885 |
| US-20110165118-A1 | 3-HETEROCYCLIC SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, HTR3C | KDM4E 1606/4885PARP1 1168/4885CA12 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.